Acetyl- l -carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy
Abstract Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth...
Saved in:
Published in | Neuroscience Vol. 167; no. 4; pp. 1168 - 1174 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Amsterdam
Elsevier
02.06.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line–derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl- l -carnitine (ALCAR; 100 mgkg−1 i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR. |
---|---|
AbstractList | Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line-derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl-l-carnitine (ALCAR; 100 mgkga1 i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR. Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line-derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl-l-carnitine (ALCAR; 100 mgkg(-1) i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR. Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line-derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl-l-carnitine (ALCAR; 100 mgkg(-1) i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR.Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line-derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl-l-carnitine (ALCAR; 100 mgkg(-1) i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR. Abstract Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to prevent or revert morphological and molecular consequences of tissue injury. On the other hand, many neurotrophins, like nerve growth factor (NGF), paired off restorative effects with hyperalgesia. Interestingly, the glial cell line–derived neurotrophic factors GDNF and Artemin (ARTN) seem to support neuron survival and to normalize abnormal pain behaviour. In the present research protein levels of NGF, GDNF and ARTN were evaluated in a rat model of peripheral neuropathy, the chronic constriction injury (CCI). NGF was increased by CCI in the ipsilateral dorsal root ganglia (DRG), in the spinal cord and in the periaqueductal grey matter (PAG). On the contrary, ARTN was decreased bilaterally in DRG, spinal cord and PAG. GDNF levels decreased in ipsilateral DRG, whereas the constriction did not modify its expression in the central nervous system districts. Repeated treatments with the antihyperalgesic and neuroregenerative compound acetyl- l -carnitine (ALCAR; 100 mgkg−1 i.p. twice daily for 15 days) was able to prevent the increase of NGF levels. In conditions of pain relief ALCAR normalized peripheral and central alterations of GDNF and ARTN levels. Characteristically, sham animals that underwent the same ALCAR treatment, showed increased levels of ARTN both in the DRG and in the spinal cord. These data offer a new point of view on the mechanism of the antihyperalgesic as well as the neuroprotective effect of ALCAR. |
Author | Di Cesare Mannelli, L Ghelardini, C Benatti, P Vivoli, E Nicolai, R Salvicchi, A Bartolini, A Koverech, A |
Author_xml | – sequence: 1 fullname: Vivoli, E – sequence: 2 fullname: Di Cesare Mannelli, L – sequence: 3 fullname: Salvicchi, A – sequence: 4 fullname: Bartolini, A – sequence: 5 fullname: Koverech, A – sequence: 6 fullname: Nicolai, R – sequence: 7 fullname: Benatti, P – sequence: 8 fullname: Ghelardini, C |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23087260$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20302919$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1r3DAQhkVJaTZp_0IRhdKTN_qwJe-lEELbFAI9NDmLsTRutNHKriQH9t9HyW7pMYNgBPNoNPO-Z-QkThEJ-cTZmjOuLrbriEuasvUYLa4FqwUm14zrN2TFey0b3bXtCVkxyVTTdkKckrOct6xG18p35FTUitjwzYo8XFos-9DQQBsLKfriI1IfbULImCmkgjsfacBHDBSio3Oq11gyfRmipGm-95aOYMuUKISCCYqfYqZuST7-OWAzlPv9e_J2hJDxwzGfk7vv326vrpubXz9-Xl3eNFb2bWla1wFsuEAQ3aCcskI5GDnvONej0oPaDKN1joEUTMHAUaC2XHOncexEXfCcfDn0ndP0d8FczM5niyFAxGnJpu-UrkexV0ktpZId7_tKfjySy7BDZ-bkd5D25p-SFfh8BCBbCGOCaH3-z0nWa_Hy5dcDh1WBR4_J2OCjr08ecI95Oy0pVnEMN1kYZn4_e_hsIa_mSdW38gkZEZ8v |
CODEN | NRSCDN |
CitedBy_id | crossref_primary_10_1007_s00213_011_2326_0 crossref_primary_10_1016_j_douler_2013_01_007 crossref_primary_10_1016_j_neulet_2018_08_051 crossref_primary_10_1007_s40263_013_0132_4 crossref_primary_10_4103_1673_5374_230297 crossref_primary_10_1016_j_neuroscience_2014_11_025 crossref_primary_10_1007_s11011_021_00773_w crossref_primary_10_3390_ijms241914841 crossref_primary_10_3390_neurosci5030018 crossref_primary_10_1016_j_bbrc_2014_01_082 crossref_primary_10_3389_fendo_2021_806819 crossref_primary_10_2174_1570159X15666170915143217 crossref_primary_10_1371_journal_pone_0037621 crossref_primary_10_1097_MOG_0b013e3283505a3b crossref_primary_10_1111_andr_13187 crossref_primary_10_1111_papr_12403 crossref_primary_10_1586_14737175_2013_814930 crossref_primary_10_1111_j_1464_410X_2011_10705_x crossref_primary_10_3390_molecules200610657 crossref_primary_10_1021_acsbiomaterials_7b00655 crossref_primary_10_1016_j_expneurol_2010_11_005 crossref_primary_10_1186_1744_8069_7_16 crossref_primary_10_1016_j_brainres_2011_01_002 crossref_primary_10_1007_s11011_023_01206_6 crossref_primary_10_1016_j_eurger_2017_01_002 crossref_primary_10_1016_j_mam_2011_10_007 crossref_primary_10_1097_01_j_pain_0000460339_23976_12 crossref_primary_10_3389_fnut_2022_853058 crossref_primary_10_1080_00207454_2022_2107515 crossref_primary_10_1155_2013_328797 crossref_primary_10_1016_j_neulet_2017_07_059 crossref_primary_10_1016_j_phrs_2021_105874 |
ContentType | Journal Article |
Copyright | IBRO 2015 INIST-CNRS Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: IBRO – notice: 2015 INIST-CNRS – notice: Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved. |
DBID | IQODW CGR CUY CVF ECM EIF NPM 7X8 7TK |
DOI | 10.1016/j.neuroscience.2010.03.017 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Neurosciences Abstracts |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic Neurosciences Abstracts |
DatabaseTitleList | Neurosciences Abstracts MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 1873-7544 |
EndPage | 1174 |
ExternalDocumentID | 20302919 23087260 1_s2_0_S0306452210003684 |
Genre | Retracted Publication Journal Article |
GroupedDBID | --- --K --M -DZ -~X .1- .55 .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXKI AAXLA AAXUO ABCQJ ABFNM ABFRF ABJNI ABLJU ABMAC ABTEW ABXDB ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMQ HVGLF HZ~ IHE J1W KOM L7B M2V M41 MO0 MOBAO N9A O-L O9- OAUVE OP~ OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SNS SPCBC SSN SSZ T5K UNMZH WUQ X7M YYP Z5R ZGI ZXP ~G- 08R AADPK AAIAV AAUGY ABPIF ABPTK ABYKQ AJBFU IQODW CGR CUY CVF ECM EIF NPM 7X8 7TK |
ID | FETCH-LOGICAL-c384t-4d5aa912ea25b6d6c26daf115117f67b69bfcdd0a3206ab1e2e7c171d7ef52543 |
ISSN | 0306-4522 1873-7544 |
IngestDate | Fri Oct 25 04:51:48 EDT 2024 Sat Oct 26 02:16:53 EDT 2024 Tue Oct 29 09:20:18 EDT 2024 Sun Oct 22 16:08:02 EDT 2023 Tue Oct 15 22:55:54 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | pain acetyl- l-carnitine periaqueductal grey matter artemin dorsal root ganglia CCI chronic constriction injury NGF glial cell line-derived neurotrophic factor GDNF ARTN nerve growth factor PAG neurorestoration DRG ALCAR Neurotrophic factor Pain Glial cell line derived neurotrophic factor Nerve growth factor |
Language | English |
License | CC BY 4.0 Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c384t-4d5aa912ea25b6d6c26daf115117f67b69bfcdd0a3206ab1e2e7c171d7ef52543 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Correction/Retraction-3 ObjectType-Article-2 ObjectType-Feature-1 |
PMID | 20302919 |
PQID | 733635188 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_856756760 proquest_miscellaneous_733635188 pubmed_primary_20302919 pascalfrancis_primary_23087260 elsevier_clinicalkeyesjournals_1_s2_0_S0306452210003684 |
PublicationCentury | 2000 |
PublicationDate | 2010-06-02 |
PublicationDateYYYYMMDD | 2010-06-02 |
PublicationDate_xml | – month: 06 year: 2010 text: 2010-06-02 day: 02 |
PublicationDecade | 2010 |
PublicationPlace | Amsterdam |
PublicationPlace_xml | – name: Amsterdam – name: United States |
PublicationTitle | Neuroscience |
PublicationTitleAlternate | Neuroscience |
PublicationYear | 2010 |
Publisher | Elsevier |
Publisher_xml | – name: Elsevier |
References | 39332810 - Neuroscience. 2024 Sep 24:S0306-4522(24)00494-9. doi: 10.1016/j.neuroscience.2024.09.041 |
References_xml | |
SSID | ssj0000543 |
Score | 2.2206645 |
SecondaryResourceType | retracted_publication |
Snippet | Abstract Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not... Damages to the nervous system are the primarily cause of neuropathy and chronic pain. Current pharmacological treatments for neuropathic pain are not able to... |
SourceID | proquest pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1168 |
SubjectTerms | Acetyl-L-carnitine Acetylcarnitine - pharmacology Analgesics - pharmacology Animals Biological and medical sciences Constriction, Pathologic - complications Fundamental and applied biological sciences. Psychology Ganglia, Spinal - metabolism Male Nerve Growth Factors - metabolism Nerve Tissue Proteins - metabolism Neurology Neuroprotective Agents - pharmacology Pain - etiology Pain - metabolism Pain Threshold Periaqueductal Gray - metabolism Peripheral Nervous System Diseases - etiology Peripheral Nervous System Diseases - metabolism Rats Rats, Sprague-Dawley Sciatic Nerve - injuries Spinal Cord - metabolism Vertebrates: nervous system and sense organs |
Title | Acetyl- l -carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0306452210003684 https://www.ncbi.nlm.nih.gov/pubmed/20302919 https://www.proquest.com/docview/733635188 https://search.proquest.com/docview/856756760 |
Volume | 167 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBbp9lIope32kT4WHUovwcGS38ew3WUpaXpoUnITsixRL6kTYqewPfS3d0a2Y4fd0MfFBOEoJvNprBnNfB8h72SikectcIxWxvEDYxwYMY7yeeSmxsjAyrd9moVXC__jMlgOBqZXtbSr0rH6eWdfyf9YFcbArtgl-w-W3U8KA_AZ7AtXsDBc_8rGE6Wrm5UzdRTmN6rcMoDgNrDUJbIXIXHIaIVlQS0fwA_b0GZJLKvtevMtV43izsgemzd1cU3vor0NJYsPjn5nHQPmHhRfc_By-UFjw4d8dK5LrCtDHWak_ex6HDCjI1fgo5SVFO7nU7cVqgj1RpuMBB6mYx1zz4nGkecgsV79jrljrPW8tRJHAzG_50cZq8V2bjn4OtdwPe6xfeqmQM8bu3Ub6CGr9uyzuFxMp2J-sZzfI_c5OCQs_Rv_6kqBYNtqGzHaZ2zJaW0d4LFfOti9PNzIEtaUqcVQjkcrdtcyf0weNeEGndTYeUIGunhKTieFrNbfb-h7aguA7cnKKclvw4nu4UQbOFELJwpwoi2caB9OtIYT7cGJ1nCiHZyekcXlxfz8ymmUOBzlxX7l-FkgZcK4ljxIwyxUPMykgWCCsciEURomqVFZ5kqPu6FMmeY6UixiWaRNgHQLz8lJsS70S0I96arIB8dg0tTnWZbEAffx676JTWbiIYnav1W0zcHwOtNls-5KwUTJhSu-YLSLegDMkirF_pCcHVhBbGq-FsGR9RLi9iGhrVkEOFE8GZOFXu9KgZygHlITHr8lDiC0DiOc5UVt0W5-eBKesOTVn-d_TR50K-YNOam2O_0WdrVVemYh-RsCxKsv |
link.rule.ids | 315,783,787,27938,27939 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Acetyl-L-carnitine+increases+artemin+level+and+prevents+neurotrophic+factor+alterations+during+neuropathy&rft.jtitle=Neuroscience&rft.au=Vivoli%2C+E&rft.au=Di+Cesare+Mannelli%2C+L&rft.au=Salvicchi%2C+A&rft.au=Bartolini%2C+A&rft.date=2010-06-02&rft.issn=1873-7544&rft.eissn=1873-7544&rft.volume=167&rft.issue=4&rft.spage=1168&rft_id=info:doi/10.1016%2Fj.neuroscience.2010.03.017&rft.externalDBID=NO_FULL_TEXT |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F03064522%2FS0306452210X00094%2Fcov150h.gif |